Patent · US Active

Efficient TCR gene editing in T lymphocytes

US12239664B2 · kind B2 · utility

0Cited by
2References
26Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 24, 2022
Grant dateMar 4, 2025
Priority date
Expiry dateApr 1, 2042

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2800/80
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present disclosure relates to engineered T cells and methods of making and using the same, as well as reagents for making the engineered T cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.